No Data
HK Stock MarketDetailed Quotes
02269 WUXI BIO
Watchlist
28.600
-0.750-2.56%
Not Open 12/11 16:08 CST
29.300High28.100Low38.82MVolume
28.600Open29.350Pre Close1.11BTurnover0.91%Turnover Ratio27.03P/E (TTM)121.74BMarket Cap77.40052wk High24.59P/E (Static)4.26BShares28.10052wk Low2.97P/B121.74BFloat Cap148.000Historical High--Dividend TTM4.26BShs Float8.333Historical Low--Dividend LFY4.09%Amplitude--Div YieldTTM28.574Avg Price500Lot Size--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About WUXI BIO Company
The Group is the world's leading open biopharmaceutical technology platform company, providing end-to-end solutions for the discovery, development and production of biopharmaceuticals. Biopharmaceuticals are a subclassification of pharmaceuticals that have revolutionized the treatment of diseases in many major treatment fields around the world. The Group's end-to-end service platform enables it to provide services covering the entire biopharmaceutical development process and to provide customers with customized solutions according to their individual service requirements at any stage of the biopharmaceutical development process. The biopharmaceutical development process generally covers five stages: (i) drug discovery, (ii) preclinical development, (iii) early (phase I and II) clinical development, (iv) late stage (phase III) clinical development, and (v) commercial production. The services required for the biopharmaceutical development process can be divided into two categories: (1) pre-IND services, which include services provided in the first two stages of the biopharmaceutical development process, and (2) post-IND services, which include services provided in the remaining three stages of the biopharmaceutical development process. The Group's business model is based on its “follow the molecule” and “win the molecule” strategy. Customer demand for the Group's services will generally increase as their biopharmaceuticals advance through the biopharmaceutical development process and eventually commercialize production. As a result, the Group's revenue from each integrated project usually also increases as the project progresses.
News
A quick look at the Hong Kong market | The Science Index fell by more than 1%, sporting goods stocks had the highest decline, and Li Ning fell by more than 14%
Domestic housing stocks and property management stocks were collectively pressured. Sunac China fell nearly 9%, Greentown China fell nearly 4%; pharmaceutical stocks generally fell; Rongchang Biotech fell nearly 7%, and Zaiding Pharmaceutical fell nearly 3%; semiconductor stocks became popular in the afternoon. Shanghai Fudan rose more than 3%, and SMIC rose more than 1%.
Hong Kong Stock Afternoon Review | Hengke Index fell more than 2%, domestic housing stocks and sporting goods stocks fell sharply, and Li Ning fell nearly 14%
Automobile stocks declined one after another. Geely Automobile fell by more than 3%, Guangzhou Automobile Group and BYD shares fell by nearly 3%; pharmaceutical stock performance was weak; Rongchang Biotech fell more than 8%, Genting Xinyao fell more than 6%; restaurant stocks were under pressure. Jiumaojiu fell nearly 5%, Haidilao fell more than 3%, and Yum China fell nearly 3%.
December 8 repurchase collection | Tencent Holdings, Pharmacology, etc. have repurchased one after another. Among them, Tencent Holdings spent HK$403 million
According to documents disclosed by the Hong Kong Stock Exchange on December 11, $Tencent Holdings (00700.HK) $ and $Pharmacology (02269.HK) $ have repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 1.32 million common shares on December 8, involving an amount of HK$403 million. The repurchase price per share ranged from HK$309 to HK$301.2 million. The cumulative number of securities repurchased so far this year (since the adoption of the General Resolution) was 109 million shares, accounting for 1.142% of the number of shares issued at the time the General Resolution was passed. ② $Pharmacology Biology (022